Pharmacokinetics of toremifene
- PMID: 2142247
- DOI: 10.1016/0022-4731(90)90019-o
Pharmacokinetics of toremifene
Abstract
The pharmacokinetics of toremifene has been investigated in man after single and multiple oral doses. Toremifene was completely absorbed without first-pass metabolism. Peak concentration in serum was achieved in 4 h. Mean half-lives of distribution and elimination were 4 h and 5 days, respectively. Kinetics was linear in the studied dose-range of 10-680 mg. Toremifene was over 99% bound to plasma proteins and extensively metabolized. The main metabolites in serum were demethyl- and deaminohydroxytoremifene. In patients receiving multiple dosing of 60 mg/day serum steady-state level of toremifene was 0.8 microgram/ml on average. The level of demethyl metabolite was twice and that of deaminohydroxy metabolite was one tenth of toremifene.
Similar articles
-
Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.Drugs Aging. 1997 Oct;11(4):261-70. doi: 10.2165/00002512-199711040-00002. Drugs Aging. 1997. PMID: 9342556 Review.
-
Metabolism of toremifene in the rat.J Steroid Biochem. 1990 Jun 22;36(3):211-5. doi: 10.1016/0022-4731(90)90007-f. J Steroid Biochem. 1990. PMID: 2142235
-
Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.Cancer Chemother Pharmacol. 1990;25(4):247-51. doi: 10.1007/BF00684880. Cancer Chemother Pharmacol. 1990. PMID: 2136809 Clinical Trial.
-
Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.Breast Cancer Res Treat. 1990 Aug;16 Suppl:S19-26. doi: 10.1007/BF01807140. Breast Cancer Res Treat. 1990. PMID: 2149280 Clinical Trial.
-
[The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients].Orv Hetil. 1991 Mar 31;132(13):683-6. Orv Hetil. 1991. PMID: 1826556 Review. Hungarian.
Cited by
-
Introduction to toremifene.Breast Cancer Res Treat. 1990 Aug;16 Suppl:S3-7. doi: 10.1007/BF01807138. Breast Cancer Res Treat. 1990. PMID: 2149282 Review.
-
Biochemical and pharmacological effects of toremifene metabolites.Cancer Chemother Pharmacol. 1990;27(1):8-12. doi: 10.1007/BF00689269. Cancer Chemother Pharmacol. 1990. PMID: 2147128
-
Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.Drugs Aging. 1997 Oct;11(4):261-70. doi: 10.2165/00002512-199711040-00002. Drugs Aging. 1997. PMID: 9342556 Review.
-
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002. Clin Pharmacokinet. 1992. PMID: 1505141 Review.
-
Pharmacokinetics of selective estrogen receptor modulators.Clin Pharmacokinet. 2003;42(4):361-72. doi: 10.2165/00003088-200342040-00004. Clin Pharmacokinet. 2003. PMID: 12648026 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources